Radiopharm Theranostics
Radiopharm Theranostics is a clinical-stage radiotherapeutics company focused on developing a pipeline of first-in-class radiopharmaceuticals for the diagnosis and treatment of cancer. The company aims to transform cancer care by delivering innovative solutions for earlier detection and personalized treatment of cancers with unmet needs.
Short position
Radiopharm Theranostics (ASX:RAD) has 1.27% of its shares on issue reported as short positions as of 16 Sept 2026, or about 54,932,710 shares. Over the past 30 days that figure has risen 1.25 percentage points, and over 90 days it has risen 1.22 percentage points. RAD is classified in the Pharmaceuticals, Biotechnology & Life Sciences industry. All figures come from official ASIC short position reports, published with a four trading-day (T+4) delay.
Price & short interest
Toggle series, zoom, and compare · ASIC daily, T+4Radiopharm Theranostics (RAD) financials
Results, ratios and statements
Latest result
Year to 30 Jun 2026 (FY26) vs FY25, figures in AUD, the reporting currency
- Revenue
- $2.8MM (source: ASX (Markit))vs $3.6M (FY25)
- ASX (Markit), as at 29 Sep 2026
- NPAT
- −$55.1MM (source: ASX (Markit))vs −$38.3M (FY25)
- ASX (Markit), as at 29 Sep 2026
- EPS (diluted)
- −$0.018T (source: Derived: trailing 12 months at year end)vs −$0.018 (FY25)
- Derived: trailing 12 months at year end, as at 29 Sep 2026
- Rev YoY
- −23.8%FY
- EPS YoY
- n/aTTM
- ASX (Markit)
- Derived: trailing 12 months at year end
Key ratios
Year to 30 Jun 2026 (FY); no balance sheet aligned with this period; prices to 9 Oct 2026
- Gross margin
- 9.5%
- Operating margin
- −2,080.5%
- Net margin
- −1,992.5%
- FCF margin
- −1,907.0%
- ROE
- n/a
- ROA
- n/a
- FCF conversion
- n/a
- Net debt (excl. leases)
- n/a
- Net debt / EBITDA
- n/a
- Current ratio
- n/a
- Interest cover
- −512.4×
- Cash dividends paid / net profit
- n/a
- Market cap
- n/a (no share count we can vouch for)
- P/E
- n/a
- P/B
- n/a (no share count we can vouch for)
Ratios use the reporting currency (AUD); market cap is in AUD. Sources: ASX (Markit) and Derived: trailing 12 months at year end, as at 29 Sep 2026.
Financial statements
Figures in AUD, the reporting currency; Yahoo Finance unless marked
| Line item | FY26 | FY25 | FY24 | FY23 |
|---|---|---|---|---|
| Revenue | $2.8MM (source: ASX (Markit)) | $3.6M | $299.2K | $292.4K |
| Gross profit | $263.4KT (source: Derived: trailing 12 months at year end) | $39.3K | $299.2K | $292.4K |
| Operating income | −$57.6MT (source: Derived: trailing 12 months at year end) | −$34.6M | −$37.2M | −$31.7M |
| EBITDA | −$56.8MT (source: Derived: trailing 12 months at year end) | −$38.2M | −$47.2M | −$34.5M |
| EBIT | −$56.8MT (source: Derived: trailing 12 months at year end) | −$38.2M | −$47.2M | −$34.5M |
| Interest expense | $112.4KT (source: Derived: trailing 12 months at year end) | $65.3K | $642.9K | $86.1K |
| Pretax income | −$56.9MT (source: Derived: trailing 12 months at year end) | −$38.2M | −$47.9M | −$34.6M |
| Tax | $54.4KT (source: Derived: trailing 12 months at year end) | $103.3K | $96.4K | $38.0K |
| NPAT | −$55.1MM (source: ASX (Markit)) | −$38.3M | −$47.9M | −$34.6M |
| Net interest income | −$112.4KT (source: Derived: trailing 12 months at year end) | $333.1K | −$225.7K | $58.9K |
| EPS basic | −$0.018T (source: Derived: trailing 12 months at year end) | −$0.018 | −$0.12 | −$0.11 |
| EPS diluted | −$0.018T (source: Derived: trailing 12 months at year end) | −$0.018 | −$0.12 | −$0.11 |
| Shares | n/a | 2.36B | 460.4M | 359.3M |
- ASX (Markit)
- Derived: trailing 12 months at year end
Financial reports
The company's own filings, newest first
- Annual Report and Form 20-FAnnual Report30 Sep 2026via asx_announcements
- Appendix 4E and Preliminary Final ReportAnnual Results28 Aug 2026via asx_announcements
- Quarterly Activities/Appendix 4C Cash Flow ReportQuarterly Report31 Jul 2026via asx_announcements
- Quarterly Activities/Appendix 4C Cash Flow ReportQuarterly Report23 Apr 2026via asx_announcements
- Half Year Report and Appendix 4D 31 December 2025Half Year Results27 Feb 2026via asx_announcements
- Quarterly Activities/Appendix 4C Cash Flow ReportQuarterly Report28 Jan 2026via asx_announcements
- DownloadFinancial Report31 Dec 2025via crawler
- DownloadFinancial Report31 Dec 2025via crawler
- DownloadFinancial Report31 Dec 2025via crawler
- DownloadFinancial Report31 Dec 2025via crawler
Showing 10 of 26 reports